NCT07100327

Brief Summary

Obesity remains a major global health challenge, with Class IV super obesity (BMI ≥ 50 kg/m²) being the most severe form. This condition is associated with numerous comorbidities including type 2 diabetes, hypertension, obstructive sleep apnea, and hyperlipidemia, which significantly reduce life expectancy and quality of life. Bariatric surgery, particularly sleeve gastrectomy (SG), has been shown to be an effective treatment for morbid obesity. While SG results in significant weight loss and improvement of comorbidities, some patients experience weight regain over time. Banded sleeve gastrectomy (BSG) has been proposed as a modification of SG to enhance long-term outcomes by providing additional restriction via a polypropylene band around the proximal gastric pouch. Although initial evidence for banded procedures suggests improved outcomes, particularly in the context of weight loss and reduced weight regain, specific evidence for Class IV obesity remains limited.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
219

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 15, 2022

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 15, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 15, 2025

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

July 17, 2025

Completed
17 days until next milestone

First Posted

Study publicly available on registry

August 3, 2025

Completed
Last Updated

August 3, 2025

Status Verified

July 1, 2025

Enrollment Period

3 years

First QC Date

July 17, 2025

Last Update Submit

July 27, 2025

Conditions

Keywords

Class IV Obese PatientsBanded versus Non-Banded Sleeve Gastrectomy

Outcome Measures

Primary Outcomes (1)

  • Total Weight Loss (TWL)

    Total Weight Loss between the 2 groups (in kilograms)

    Measured at 6, 12, 24 and 36 months postoperatively

Secondary Outcomes (9)

  • Resolution of associated medical problems

    6, 12, 24, and 36 months.

  • Resolution of associated medical problems

    6, 12, 24, and 36 months.

  • Resolution of associated medical problems

    6, 12, 24, and 36 months.

  • Resolution of associated medical problems

    6, 12, 24, and 36 months.

  • Complications

    post operative, 12, 24, and 36 months

  • +4 more secondary outcomes

Study Arms (2)

Banded Group

ACTIVE COMPARATOR

Placement of a 1.5 x 5.5 cm polypropylene band

Procedure: Band

Non-Banded Group

PLACEBO COMPARATOR

Standard laparoscopic sleeve gastrectomy

Procedure: Non-Band

Interventions

BandPROCEDURE

Laparoscopic sleeve gastrectomy with the placement of a 1.5 x 5.5 cm polypropylene band around the proximal gastric pouch to enhance restriction.

Banded Group
Non-BandPROCEDURE

Standard laparoscopic sleeve gastrectomy where approximately 75-80% of the stomach is resected to form a tubular structure

Non-Banded Group

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Adults aged 18-60 years
  • BMI ≥ 50 kg/m² (Class IV obesity)
  • No prior gastrointestinal surgeries
  • No significant psychiatric or medical contraindications to surgery
  • Ability to provide informed consent

You may not qualify if:

  • BMI \< 50 kg/m²
  • Refusal to undergo band placement
  • Active reflux disease or PPI use
  • Prior bariatric surgery
  • Pregnancy plans during the study period
  • Active cancer or life-limiting illness
  • Substance abuse or non-compliance with postoperative care
  • Gastroesophageal reflux disease.
  • Hiatal hernia.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The surgical department of Medical Research Institute Hospital, Alexandria University

Alexandria, 21531, Egypt

Location

MeSH Terms

Interventions

Chromosome BandingChloride-Bicarbonate Antiporters

Intervention Hierarchy (Ancestors)

Cytogenetic AnalysisCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisStaining and LabelingHistocytological Preparation TechniquesHistological TechniquesInvestigative TechniquesGenetic TechniquesAntiportersIon PumpsMembrane Transport ProteinsCarrier ProteinsProteinsAmino Acids, Peptides, and ProteinsSLC4A ProteinsSolute Carrier ProteinsMembrane GlycoproteinsMembrane Proteins

Study Officials

  • Mohamed Ashour, Ph.D. (Professor)

    The surgical department of Medical Research Institute Hospital, Alexandria University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: * Banded Group: Laparoscopic sleeve gastrectomy with the placement of a 1.5 x 5.5 cm polypropylene band around the proximal gastric pouch to enhance restriction. * Non-Banded Group: Standard laparoscopic sleeve gastrectomy where approximately 75-80% of the stomach is resected to form a tubular structure.
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of General surgery

Study Record Dates

First Submitted

July 17, 2025

First Posted

August 3, 2025

Study Start

June 15, 2022

Primary Completion

June 15, 2025

Study Completion

July 15, 2025

Last Updated

August 3, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will share

The analysis will be performed on a blinded dataset after completing the medical/scientific review. All protocol violations will be identified and resolved, and the dataset will be declared complete. All data will be collected in a data management system (Castor EDC, Amsterdam, The Netherlands; https://www.castoredc.com), handled according to Good Clinical Practice guidelines, Data Protection Directive certificate, and complied with Title 21 CFR Part 11. Furthermore, the data centers where all the research data will be stored are certified according to ISO27001, ISO9001, and Dutch NEN7510. Can be asked by the contact person

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
whole study period
Access Criteria
Ask contact person

Locations